The Cooper Companies Completes Voluntary Tender Offer for Origio
PLEASANTON, Calif., (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. today announced it has completed the purchase of 31,561,239 shares, or 96.99% of the issued and outstanding shares of Origio a/s, a Danish company listed on the Oslo Stock Exchange (OSE:ORO). The purchase of the shares was pursuant to a voluntary public tender offer for the outstanding shares and warrants of Origio that commenced June 4, 2012. To acquire all outstanding shares of Origio, Cooper will now proceed with the mandatory redemption of the remaining Origio shares in accordance with the Danish Companies Act.
Origio is a leading global in-vitro fertilization (IVF) medical device company that develops, manufactures and distributes highly specialized products that target IVF treatment with a goal to make fertility treatment safer, more efficient and convenient. Based in Malov, Denmark, Origio has approximately 320 employees and generated sales of DKK 370 million (approximately US$65 million) in 2011.
About The Cooper Companies
Cooper is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company(TM) with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support.
CooperSurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has over 7,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.